China Pharma Holdings Cites No Known Cause for Unusual Market Activity
China Pharma Holdings stated it is unaware of any undisclosed events or business developments that could explain recent unusual trading activity in its stock.
China Pharma Holdings, Inc. announced on July 15, 2026, that it is unaware of any non-public information or business developments that could account for recent unusual trading activity in its common stock. The NYSE American had contacted the company due to the stock's activity on July 10, 13, and 15.
The company, a fully-integrated specialty pharmaceuticals firm in China, stated that while it generally does not comment on unusual market activity, it has not disclosed any material information that would explain the trading fluctuations. China Pharma Holdings develops, manufactures, and markets a range of pharmaceutical products targeting conditions with high incidence and mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases.
Its business model focuses on market demand, supported by eight GMP-certified product lines and a nationwide distribution network. The company's subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province.
The statement comes after the company's stock experienced notable trading volume and price movements in recent sessions, prompting the exchange's inquiry. China Pharma Holdings has reiterated its adherence to public disclosure requirements.